- Molecular NamePantoprazole
- SynonymPantoprazol [INN-Spanish]; Pantoprazole Na; Pantoprazole Sodium; Pantoprazolum [INN-Latin]; Pantoprozole
- Weight383.375
- Drugbank_IDDB00213
- ACS_NO102625-70-7
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.29
- pka3.92; 8.19 (21° to 22°)
- LogD (pH=7, predicted)1.27
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.24
- LogSw (predicted, AB/LogsW2.0)6.51
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors1
- No.of HBond Acceptors7
- No.of Rotatable Bonds7
- TPSA105.54
- StatusFDA approved
- AdministrationOral and intravenous
- PharmacologyA proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability77.0
- Protein binding98.0
- Volume of distribution (VD)0.15 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.
- Half life1~2 h in good metabolisers (pantoprazole); 6 h in poor metabolisers (drug); 1.5 h (metabolites).
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityMost freequent adverse events reported as drug related were headache, diarrhea, flatulence, abdominal pain, rash, eructation, insomnia, hypertriglicemia, abnormal liver function tests, nausea, vomiting. Parenteral.
- LD50 (rat)N/A
- LD50 (mouse)N/A